VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN

Abstract. We studied immune resistance efficiency of vaccination against influenza A/California/7/2009(H1N1)v in women at second trimester of physiological pregnancy in a blind, placebocontrolled study. The first group included thirty pregnant women who were injected by univalent subunit “MonoGrippol plus” vaccine. The second group consisted of thirty-seven pregnant women immunized by trivalent “Grippol plus” vaccine. Thirty-one pregnant women (III group) received placebo treatment. Non-pregnant women (IV group) were injected with “MonoGrippol plus”. We did not find any differences in clinical features of vacccine-challenged time period in pregnant women from groups I-III. Notably, sufficient numbers of women were found to be seroprotected 1 month post-vaccination (I group, 80.0% ; II group, 75.7% ; IVgroup, 80.6% ) with high levels seroconversion (I group, 46.6%; II group, 51.4%; IV group, 53.3%). Within 9-10 months after vaccination, a decreased seroprotection was revealed in II group of pregnant women. More stable specific immunity levels were detected for the groups immunized with univalent vaccine.Hence, the local subunit adjuvant “MonoGrippol plus” and “Grippol plus” vaccines were shown to exibit a high immune resistance efficiency profile and clinical safety, when used in pregnant women, thus presuming an extended application field for these biological drugs in public health service. State of pregnancy seems not to be a limiting condition for induction of specific immune resistance

RENAL AND CORONARY PREDICTORS OF POST-MYOCARDIAL REVASCULARISATION PROGNOSIS IN PATIENTS WITH CORONARY HEART DISEASE

Aim. To assess the impact of renal and local coronary risk factors (RFs) on cardiovascular survival in patients with coronary heart disease (CHD) before and after myocardial revascularisation. Material and methods. The study included 90 CHD patients with indications for myocardial revascularisation. In all participants, the presence of renal RFs (microalbuminuria (MAU) and increased levels of β2 -microglobulin (β2 -MG)) was assessed at different intervention stages. In addition, the number of coronary arteries (CA) affected by atherosclerosis, as well as CA atherosclerosis severity, was assessed. Results. Among the majority of CHD patients with myocardial revascularisation indications, MAU was observed at all intervention stages. The endpoint incidence was associated with MAU, β2 -MG levels, the number of CA affected by atherosclerosis and CA with hemodynamically non-significant stenosis. The levels of β2 -MG significantly correlated with atherosclerotic plaque growth rate. Conclusion. The increased risk of coronary events was associated with elevated levels of MAU and β2 -MG and the increased number of CA affected by atherosclerosis and CA with hemodynamically non-significant stenosis. Elevated CV risk was linked to β2 -MG levels of ≥0,1 ng/ml. The levels of β2 -MG increased in parallel with the CHD progression